Dapagliflozin

For research use only.

Catalog No.S1548 Synonyms: BMS-512148

20 publications

Dapagliflozin Chemical Structure

CAS No. 461432-26-8

Dapagliflozin (BMS-512148) is a potent and selective hSGLT2 inhibitor with EC50 of 1.1 nM, exhibiting 1200-fold selectivity over hSGLT1. Phase 4.

Size Price Stock Quantity  
10mM (1mL in DMSO) RMB 2293.58 In stock
RMB 1409.09 In stock
RMB 2636.59 In stock
RMB 7922.15 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Dapagliflozin has been cited by 20 publications

Purity & Quality Control

Choose Selective SGLT Inhibitors

Biological Activity

Description Dapagliflozin (BMS-512148) is a potent and selective hSGLT2 inhibitor with EC50 of 1.1 nM, exhibiting 1200-fold selectivity over hSGLT1. Phase 4.
Features More potent stimulator of glucosuria than other SGLT2 inhibitors.
Targets
hSGLT2 [1]
(CHO cells)
1.1 nM(EC50)
In vitro

Dapagliflozin is not sensitive to hSGLT1 with a 1200-fold IC50. [1] Dapagliflozin is 32-fold more potent than phlorizin against hSGLT2 but 4-fold less than phlorizin against hSGLT1. Dapagliflozin is highly selective versus GLUT transporters and displays 8–9% inhibition in protein-free buffer at 20 μM and virtually no inhibition in the presence of 4% bovine serum albumin. [2] Dapagliflozin has good permeability across Caco-2 cell membranes and is a substrate for P-glycoprotein (P-gp) but not a significant P-gp inhibitor. Dapagliflozin is stable in rat, dog, monkey, and human serum at 10 μM. Dapagliflozin shows no inhibitory responses or induction to human P450 enzymes. The in vitro metabolic pathways Dapagliflozin are glucuronidation, hydroxylation, and O-deethylation. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CHO cells M37OfWZ2dmO2aX;uJIF{e2G7 M3:wOlIhcA>? NF\acnFKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSyJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgX|E1S12jbIDoZU1u\XSqeXytSE1odHWlb4D5doFvd3OrZHWgeZB1[WunIHHmeIVzKDJiaILzJIJ6KGyrcYXp[EB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDJR|UxRTBwMECwOFkh|ryP NG\hVVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESzOFkxQSd-MkC0N|Q6ODl:L3G+
CHOK1 cells M{\jdmZ2dmO2aX;uJIF{e2G7 M4Lj[lMhcA>? NYfSSlBSUW6qaXLpeIlwdiCxZjDoeY1idiCVR1zUNkBmgHC{ZYPz[YQhcW5iQ1jPT|Eh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDbNVREZS2DTVegeZB1[WunIHHmeIVzKDNiaILzJIJ6KG2rY4LvZoV1[SC|Y3nueIltdGG2aX;uJINwfW62aX7nJIFv[Wy7c3nzMEBKSzVyPUCuNFAyKM7:TR?= M1OyblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OESyOlE5Lz5{NEi0NlYyQDxxYU6=
HEK293.ETN cells NFj6SZFHfW6ldHnvckBie3OjeR?= NY\x[VJJOS53IHi= NWDBZ2k6UW6qaXLpeIlwdiCxZjDoeY1idiCVR1zUNkB1emGwc3\lZ5Rm\CCrbjDISWszQTNwRWTOJINmdGy|IHHzd4V{e2WmIHHzJGFOTyC3cIThb4Uh[W[2ZYKgNU42KGi{czDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDJR|UxRTBwMEC2O{DPxE1? MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh7NkO3OEc,OTl6OU[zO|Q9N2F-
COS-7 cells NUDqNoF{TnWwY4Tpc44h[XO|YYm= NVr0eWM6OiCq MmXNTY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMTD0doFve2[nY4Tl[EBqdiCFT2OtO{Bk\WyuczDhd5Nme3OnZDDhd{BCVUdidYD0ZYtmKGGodHXyJFIhcHK|IHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFnDOVA:OC56OTFOwG0> NVTFblZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4PVY{PzRpPkG5PFk3Ozd2PD;hQi=>
CHO M4rWXmZ2dmO2aX;uJIF{e2G7 MkPzTY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMjDlfJBz\XO|ZXSgbY4hS0iRIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhYzF2Q23BUWch[WOldX31cIF1cW:wLDDFR|UxKD1iMD6wNFEyKM7:TT6= Mkm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NkC2NVgoRjF6Mk[wOlE5RC:jPh?=
CHO NFj5PI9HfW6ldHnvckBie3OjeR?= MUDJcohq[mm2aX;uJI9nKHKjdDDTS2xVOiCneIDy[ZN{\WRiaX6gR2hQKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gX|E1S12DTVegZYNkfW23bHH0bY9vNCCHQ{WwJF0hOC5yMEOg{txONg>? NYnuXFJORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOlA3OThpPkG4NlYxPjF6PD;hQi=>
CHO NXHUUHBsTnWwY4Tpc44h[XO|YYm= Mkm5TY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMTDlfJBz\XO|ZXSgbY4hS0iRIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhYzF2Q23BUWch[WOldX31cIF1cW:wLDDFR|UxKD1iMT6zPUDPxE1w MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ4ME[xPEc,OTh{NkC2NVg9N2F-
HEK293.ETN NYjmVHYzTnWwY4Tpc44h[XO|YYm= M1PEdGlvcGmkaYTpc44hd2ZiaIXtZY4hW0eOVEKg[ZhxemW|c3XkJIlvKEiHS{K5N{5GXE5iY3XscJMh[XO|ZYPz[YQh[XNibXX0bJltNWGucHjhMWQuY1VvMUTDYYdtfWOxcInyZY5we2mmZTD1dJRic2ViYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NEA:KDBwMEC2O{DPxE1w MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTdyMEOxPEc,OTl5MECzNVg9N2F-
COS7 NXO5XW5ZTnWwY4Tpc44h[XO|YYm= NFHSOFZKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSxJIV5eHKnc4Pl[EBqdiCjZoLpZ4FvKGe{ZXXuJI1wdmuneTDDU3M4KGOnbHzzJIF{e2W|c3XkJIF{KG2ndHj5cE1idHCqYT3EMXtWNTF2Q23ncJVkd3C7cnHuc5Nq\GVidYD0ZYtmKGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUCgQUAxNjh6NTFOwG0v MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTdyMEOxPEc,OTl5MECzNVg9N2F-
HEK293 MnzqSpVv[3Srb36gZZN{[Xl? M3qxcGlvcGmkaYTpc44hd2ZiaIXtZY4hW0eOVEGg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGuxOGNe[WyyaHGtcYV1cHmuZ3z1Z49xgXKjbn;zbYRmKHWydHHr[UwhUUN3MDC9JFAvQDFizszNMi=> NYO3WpRWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3PFU1OzVpPkG5O|g2PDN3PD;hQi=>
CHO NXP3eZhYTnWwY4Tpc44h[XO|YYm= MUeyJIhzew>? NH\abVBKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSyJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC|b3TpeY0u\GWyZX7k[Y51KG2ndHj5cE1idHCqYT3EMXtWNTF2Q23ncJVkd3C7cnHuc5Nq\GVidYD0ZYtmKGGodHXyJFIhcHK|LDDJR|UxKD1iMD6wNFE1KM7:TT6= M1XlflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUS5OlU{Lz5{MEG0PVY2OzxxYU6=
CHO NVjvVohOTnWwY4Tpc44h[XO|YYm= M2K0WlIhcHK| MlvpTY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMTDlfJBz\XO|ZXSgbY4hS0iRIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yhe2:maYXtMYRmeGWwZHXueEBu\XSqeXytZYxxcGFvRD3bWU0yPEOfZ3z1Z49xgXKjbn;zbYRmKHWydHHr[UBi\nSncjCyJIhzeyxiSVO1NEA:KDFwMjFOwG0v MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2OU[1N{c,OjBzNEm2OVM9N2F-
CHO M1Xmd2Z2dmO2aX;uJIF{e2G7 NUHsbFJUUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDTS2xVOiCneIDy[ZN{\WRiaX6gR2hQKGOnbHzzJIJ6KGyrcYXp[EB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDJR|UxKD1iMD6wNFA1QSEQvF2u NH74emU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG4NVQ5Pid-MkCxPFE1QDZ:L3G+
HEK293 NInnTXlHfW6ldHnvckBie3OjeR?= NW\SN3duOS53IHjydy=> NUD3e4VUUW6qaXLpeIlwdiCxZjDoeY1idiCVR1zUNkBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gX|E1S12jbIDoZU1u\XSqeXytSE1odHWlb4D5doFvd3OrZHWgeZB1[WunIHHmeIVzKDFwNTDodpMh[nlibHnxeYllKHOlaX70bYxt[XSrb36gZ492dnSrbnesJGlEPTBiPTCwMlAxPjdizszNMi=> MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODV5NkW3PEc,OjB3N{[1O|g9N2F-
COS7 Mn30SpVv[3Srb36gZZN{[Xl? MnXPNkBpenN? MUDJcohq[mm2aX;uJI9nKGi3bXHuJHNIVFRzIHX4dJJme3OnZDDpckBi\nKrY3HuJIdz\WWwIH3vcotmgSCFT2O3JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiW{G0R31idHCqYT3t[ZRpgWxvRD3ncJVkd3C7cnHuc5Nq\GVidYD0ZYtmKGGodHXyJFIhcHK|IHL5JIxqeXWrZDDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCLQ{WwJF0hOC56OTFOwG0v NF7T[Wo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEW3OlU4QCd-MkC1O|Y2Pzh:L3G+
CHO M13DO2Z2dmO2aX;uJIF{e2G7 NVvTS2tLOiCqcoO= MYPJcohq[mm2aX;uJI9nKGi3bXHuJHNIVFR{IHX4dJJme3OnZDDpckBEUE9iY3XscJMh[XO|ZYPz[YQh[XNic3;kbZVuNWSncHXu[IVvfCCdMUTDYU1idHCqYT3t[ZRpgWxvRD3ncJVkd3C7cnHuc5Nq\GVidYD0ZYtmKGGodHXyJFIhcHK|IHL5JIxqeXWrZDDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCHQ{WwJF0hOC5yMEOg{txONg>? NVvFT3p7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxNlg2QTJpPkKxNVI5PTl{PD;hQi=>
CHO M37C[WZ2dmO2aX;uJIF{e2G7 MYeyJIhzew>? NEP0dGRKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSxJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgd49lcXWvLXTldIVv\GWwdDDbNVREZS2jbIDoZU1u\XSqeXytSE1odHWlb4D5doFvd3OrZHWgeZB1[WunIHHmeIVzKDJiaILzJIJ6KGyrcYXp[EB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDFR|UxKD1iMD60Nlg2KM7:TT6= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF{OEW5Nkc,OjFzMki1PVI9N2F-
CHO MV;GeY5kfGmxbjDhd5NigQ>? Ml7QNkBpenN? NFfTd2ZKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSyJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCdMUTDYYFteGijLX3leIh6dC2GLXfseYNweHm{YX7vd4ll\SC3cIThb4Uh[W[2ZYKgNkBpenNiYomgcIlyfWmmIIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUCgQUAxNjByMES5JO69VS5? Mln0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzOUOzNFgoRjJzMUmzN|A5RC:jPh?=
CHO NY\YcYZmTnWwY4Tpc44h[XO|YYm= Mn;4OlAhdWmwcx?= MVXJcohq[mm2aX;uJI9nKGi3bXHuJHNIVFR{IHX4dJJme3OnZDDpckBEUE9iY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBcOTSFXT3hcJBp[S2vZYTofYwuTC2pbIXjc5B6emGwb4Pp[IUhfHKjboPwc5J1KGGodHXyJFYxKG2rboOgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzygTWM2OCB;IECuNFA1KM7:TT6= Mn\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|OUixNlQoRjJzM{m4NVI1RC:jPh?=
CHO M3TzemZ2dmO2aX;uJIF{e2G7 M1;5c|YxKG2rboO= M2nvU2lvcGmkaYTpc44hd2ZiaIXtZY4hW0eOVEKg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFtzNFPdMYFteGijLX3leIh6dC2GLXfseYNweHm{YX7vd4ll\SC2cnHud5BwenRiYX\0[ZIhPjBibXnud{BjgSC|Y3nueIltdGG2aX;uJINwfW62aX7nJIlvKHC{ZYPlcoNmKG:oIEGwNEUheGyjc33hMEBKSzVyIE2gNE4xOjJizszNMi=> NWHl[GdJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzPVgyOjRpPkKxN|k5OTJ2PD;hQi=>
CHO MXzGeY5kfGmxbjDhd5NigQ>? MoD0OlAhdWmwcx?= NVXVVpVHUW6qaXLpeIlwdiCxZjDoeY1idiCVR1zUNUBmgHC{ZYPz[YQhcW5iQ1jPJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiW{G0R30u[WyyaHGtcYV1cHmuLVSt[4x2[2:yeYLhco9{cWSnIITyZY5{eG:{dDDh[pRmeiB4MDDtbY5{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUCgQUAxNjN5IN88UU4> M17Fc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{m4NVI1Lz5{MUO5PFEzPDxxYU6=
CHO NV3O[|lsTnWwY4Tpc44h[XO|YYm= MknPOlAhdWmwcx?= MXXJcohq[mm2aX;uJI9nKFOJTGS2JIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCdMUTDYU1idHCqYT3t[ZRpgWxvRD3ncJVkd3C7cnHuc5Nq\GVidILhcpNxd3K2IHHmeIVzKDZyIH3pcpMh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whUUN3MDC9JFAvOzhizszNMi=> M{eyVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{m4NVI1Lz5{MUO5PFEzPDxxYU6=
CHO NIW5TpNHfW6ldHnvckBie3OjeR?= MnHVNkBpenN? MVvJcohq[mm2aX;uJI9nKGi3bXHuJHNIVFR{IHX4dJJme3OnZDDpckBEUE9iY3XscJMh[XO|ZYPz[YQh[XNiW{G0R30u[WyyaHGtcYV1cHmuLVSt[4x2[2:yeYLhco9{cWSnIIXweIFs\SCjZoTldkAzKGi{czDifUBtcXG3aXSgd4NqdnSrbHzheIlwdiClb4XueIVzNCCLQ{WwJF0hOC5yMEC0PUDPxE1w MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTVzNECxOEc,OjF3MUSwNVQ9N2F-
CHO NGO2Z5pHfW6ldHnvckBie3OjeR?= NWe3PG1FPjBibXnudy=> NV\LfHJPUW6qaXLpeIlwdiCxZjDoeY1idiCVR1zUNkBmgHC{ZYPz[YQhcW5iQ1jPJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiW{G0R30uT2y3Y3;z[UB2eHSja3WgeZNqdmdiW{G0R30udWW2aInsJIdtfWOxcInyZY5we2mmZTDh[pRmeiB4MDDtbY5{KGK7IH3pZ5Jw[mW2YTDwcIF1\SClb4XueIlv\yxiSVO1NEA:KDBwMECzJO69VS5? NUj3UY9SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1OlU1QTdpPkKxOVY2PDl5PD;hQi=>
CHO M3fTeGZ2dmO2aX;uJIF{e2G7 NWTGUXp6UW6qaXLpeIlwdiCxZjDoeY1idiCVR1zUNkBmgHC{ZYPz[YQhcW5iQ1jPJINmdGy|IIXzbY5oKG2ndHj5cE1idHCqYT3EMYdtfWOxcInyZY5we2mmZTDifUBtcXG3aXSgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NEA:KDBwMECxN|Uh|ryPLh?= NHrvfFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW5Nlc6PCd-MkG1PVI4QTR:L3G+
COS7 NEDzSXFHfW6ldHnvckBie3OjeR?= Ml3xNkBpenN? MUXJcohq[mm2aX;uJI9nKGi3bXHuJHNIVFR{IHX4dJJme3OnZDDpckBi\nKrY3HuJIdz\WWwIH3vcotmgSCFT2O3JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiW{G0R30udWW2aInsMYFteGijLVSt[4x2[2:yeYLhco9{cWSnIIXweIFs\SCjZoTldkAzKGi{czDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pIHnuJJBz\XOnbnPlJI9nKDJ3IDWgbJVu[W5icHzhd41iNCCLQ{WwJF0hOC5yMEOyJO69VS5? NIjjNlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUezO|I3Pid-MkG3N|czPjZ:L3G+
293 NH;2bVBHfW6ldHnvckBie3OjeR?= Moe3NU42KGi{cx?= NUPVRpJUUW6qaXLpeIlwdiCxZjDoeY1idiCVR1zUNUBmgHC{ZYPz[YQhcW5iaIXtZY4hOjl|IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhYzF2Q22tcYV1cHmuLXHsdIhiNURvZ3z1Z49xgXKjbn;zbYRmKHWydHHr[UBi\nSncjCxMlUhcHK|IHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmdiaX6gdJJme2WwY3Wgc4YhOjViJTDoeY1idiCybHHzcYEtKEmFNUCgQUA{NjFizszNMi=> NFrWPXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUezO|I3Pid-MkG3N|czPjZ:L3G+
CHO M1PXOmZ2dmO2aX;uJIF{e2G7 NH;R[ZMzKGi{cx?= M1jZVmlvcGmkaYTpc44hd2ZiaIXtZY4hW0eOVEKg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YhYzF2Q22tcIFj\WynZDDBUWch[W[2ZYKgNkBpenNiYomgcIlyfWmmIIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUCgQUAxNjByMUO1JO69VS5? MnnTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6NkiyN|koRjJzOE[4NlM6RC:jPh?=
CHO NUDVfmFpTnWwY4Tpc44h[XO|YYm= MorENkBpenN? NFXYdIhKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSyJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgX|E1S11vYXzwbIEudWW2aInsMWQu\2y3Y3;wfZJidm:|aXTlJJVxfGGtZTDh[pRmeiB{IHjyd{BjgSCuaYH1bYQhe2OrboTpcIxifGmxbjDjc5VvfGmwZzygTWM2OCB;IECuNFAxPDlizszNMi=> Mnz1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7ME[5OVMoRjJzOUC2PVU{RC:jPh?=
CHO-K1 NGK3bmxHfW6ldHnvckBie3OjeR?= NEDXdnlKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSyJIV5eHKnc4Pl[EBqdiCFSF:tT|Eh[2WubIOgZpkhYzF2Q23BUWchfXC2YXvlJIF{e2G7LDDJR|UxKD1iMD6wNFE{KM7:TT6= M2ixRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkWyNlU2Lz5{Mk[1NlI2PTxxYU6=
CHO-K1 NUDSN4FETnWwY4Tpc44h[XO|YYm= NFO1R2VKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSxJIV5eHKnc4Pl[EBqdiCFSF:tT|Eh[2WubIOgZpkhYzF2Q23BUWchfXC2YXvlJIF{e2G7LDDJR|UxKD1iMD64JO69VS5? NYL1VHNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2OVIzPTVpPkKyOlUzOjV3PD;hQi=>
CHO-K1 MnzUSpVv[3Srb36gZZN{[Xl? NHnxfJcyOjBibXnudy=> NYXOfGJRUW6qaXLpeIlwdiCxZjDoeY1idiCVR1zUNkBmgHC{ZYPz[YQhcW5iQ1jPMWsyKGOnbHzzJIlv[3WkYYTl[EBnd3JiMUKwJI1qdnNiYYSgN|ch\GWpQzDifUBcOTSFXT3BUWchfXC2YXvlJIF{e2G7LDDFR|UxKD1iMD6wNFI1KM7:TT6= NGTrS4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkixPFA1OCd-MkK4NVgxPDB:L3G+
CHO-K1 NV[1UlNPTnWwY4Tpc44h[XO|YYm= NHvJToUyOjBibXnudy=> MW\Jcohq[mm2aX;uJI9nKGi3bXHuJHNIVFRzIHX4dJJme3OnZDDpckBEUE9vS{GgZ4VtdHNiaX7jeYJifGWmIH\vdkAyOjBibXnud{BifCB|NzDk[YdEKGK7IGuxOGNeNUGPRzD1dJRic2ViYYPzZZktKEWFNUCgQUAxNjV7MzFOwG0v NITxbI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkixPFA1OCd-MkK4NVgxPDB:L3G+
CHO MYDGeY5kfGmxbjDhd5NigQ>? MYq0OUBucW6| MnnoTY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMjDlfJBz\XO|ZXSgbY4hS0iRIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yhe2:maYXtMYRmeGWwZHXueEBcOTSFXX3leIh6dC2jbIDoZU1FNWeudXPvdJlz[W6xc3nk[UB2eHSja3WgZYZ1\XJiNEWgcYlveyxiSVO1NEA:KDBwMECxN{DPxE1w NVe1R5JiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4PFk{PTFpPkKyPFg6OzVzPD;hQi=>
CHO MV3GeY5kfGmxbjDhd5NigQ>? MmXxOFUhdWmwcx?= MX\Jcohq[mm2aX;uJI9nKGi3bXHuJHNIVFRzIHX4dJJme3OnZDDpckBEUE9iY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB{d2SrdX2t[IVx\W6mZX70JHsyPEOfbXX0bJltNWGucHjhMWQu\2y3Y3;wfZJidm:|aXTlJJVxfGGtZTDh[pRmeiB2NTDtbY5{NCCLQ{WwJF0hOC56IN88UU4> Mn3ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6OEmzOVEoRjJ{OEi5N|UyRC:jPh?=
CHOK1 NGHX[YtHfW6ldHnvckBie3OjeR?= NX\mUItVOyCqcoO= MXfJcohq[mm2aX;uJI9nKGi3bXHuJHNIVFRzIHX4dJJme3OnZDDpckBEUE:NMTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFtzNFPdMWFOTyC3cIThb4Uh[W[2ZYKgN{BpenNiYomgcYlkem:kZYThJJNkcW62aXzsZZRqd25iY3;1cpRqdmdiYX7hcJl{cXNuIFnDOVAhRSByLki5NUDPxE1w NVLObZh6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OFI3OThpPkK0PFQzPjF6PD;hQi=>
CHO MkXkSpVv[3Srb36gZZN{[Xl? NF3IbWEzKGi{cx?= MUHJcohq[mm2aX;uJI9nKGi3bXHuJHNIVFR{IHX4dJJme3OnZDDpckBEUE9iY3XscJMh[XO|ZYPz[YQh[XNiW{G0R30u[WyyaHGtcYV1cHmuLVSt[4x2[2:yeYLhco9{cWSnIIXweIFs\SCjZoTldkAzKGi{czDifUBtcXG3aXSgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NEA:KDBwMECwOFkh|ryPLh?= M3X6e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwNlk4Lz5{NEmwNFI6PzxxYU6=
CHO NYDtTHRlTnWwY4Tpc44h[XO|YYm= MWOyJIhzew>? MXPDc41x\XSrdHn2[UBqdmirYnn0bY9vKG:oIH\1cIwudGWwZ4ToJIh2dWGwIGPHUHQzKGW6cILld5Nm\CCrbjDDTG8h[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDzc4RqfW1vZHXw[Y5l\W62IGuxOGNeNWGucHjhMY1mfGi7bD3EMYdtfWOxcInyZY5we2mmZTD1dJRic2ViYX\0[ZIhOiCqcoOgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzygTWM2OCB;IECuNFA2KM7:TT6= MofOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUCyOVQoRjJ3NkWwNlU1RC:jPh?=
CHO NGX3O4hHfW6ldHnvckBie3OjeR?= NH30ZYYyOjBibXnudy=> NUjK[3JuUW6qaXLpeIlwdiCxZjDoeY1idiCVR1zUNkBmgHC{ZYPz[YQhcW5iQ1jPJINmdGy|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKHWydHHr[UBw\iCdMUTDYWFOTyCjZoTldkAyOjBibXnud{BjgSCWb4DDc5VvfCCvZYToc4QtKEmFNUCgQUAxNjByMUWg{txONg>? M2HWSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NES3O|kyLz5{OES0O|c6OTxxYU6=
CHO NXvzPXV1TnWwY4Tpc44h[XO|YYm= NVPYTHZYOTJyIH3pcpM> NHf3WnRKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSxJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hfXC2YXvlJI9nKFtzNFPdRW1IKGGodHXyJFEzOCCvaX7zJIJ6KFSxcFPveY51KG2ndHjv[EwhUUN3MDC9JFAvPjJ7IN88UU4> NYS1OIlvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0OFc4QTFpPkK4OFQ4PzlzPD;hQi=>
CHO Mn3tSpVv[3Srb36gZZN{[Xl? NV\oe2FGOSCqch?= NGXFOXNKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSyJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKFtzNFPdRW1IKHWydHHr[UBi\nSncjCxJIhzKGK7IH3pZ5Jw[mW2YTDjc5VvfGmwZzDt[ZRpd2RuIFXDOVAhRSByLkCwNkDPxE1w MoLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{MU[1OlAoRjJ7MkG2OVYxRC:jPh?=
CHO NW\p[mJSTnWwY4Tpc44h[XO|YYm= M3L0XFEhcHJ? MnfuTY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMTDlfJBz\XO|ZXSgbY4hS0iRIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBcOTSFXVHNS{B2eHSja3WgZYZ1\XJiMTDodkBjgSCvaXPyc4JmfGFiY3;1cpRqdmdibXX0bI9lNCCHQ{WwJF0hOC56NjFOwG0v NH\VboE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUKxOlU3OCd-MkmyNVY2PjB:L3G+
CHO NXPOWHdQTnWwY4Tpc44h[XO|YYm= NFnxVXAyKGi{ NFzjVVdKdmirYnn0bY9vKG:oIH\1cIwudGWwZ4ToJIh2dWGwIGPHUHQzKGW6cILld5Nm\CCrbjDDTG8h[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iW{G0R30udWW2aInsJIFteGijLVSt[4x2[2:yeYLhco9{cWSnIIXweIFs\SCjZoTldkAyKGi{IHL5JIxqeXWrZDDzZ4lvfGmubHH0bY9vKGOxdX70bY5oKG2ndHjv[EwhUUN3MDC9JFAvODBzMEWg{txONg>? NX;pSHc{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3OlQ4PDJpPkK5O|Y1PzR{PD;hQi=>
HEK293 MlXwSpVv[3Srb36gZZN{[Xl? NYPFRY9SOTBibXnudy=> M1fBcmlvcGmkaYTpc44hd2ZiaIXtZY4hW0eOVEKg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCdMUTDYU1CVUdidYD0ZYtmKHC{ZXnuZ5Vj[XSnZDDmc5IhOTBibXnud{Bnd2yub4fl[EBjgSCdMUTDYU1CVUdiYXTkbZRqd25iYX7kJI1m[XO3cnXkJIFnfGW{IEKgbJJ{KGK7IHzpdZVq\CC|Y3nueIltdGG2aX;uJINwfW62aX7nJI1mfGixZDygTWM2OCB;IECuNFAyPCEQvF2u NVvOSpJERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm5OVQ3QDJpPkK5PVU1Pjh{PD;hQi=>
HEK293 MUfGeY5kfGmxbjDhd5NigQ>? MUOxNEBucW6| MkmyTY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMTDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKFtzNFPdMWFOTyC3cIThb4UheHKnaX7jeYJifGWmIH\vdkAyOCCvaX7zJIZwdGyxd3XkJIJ6KFtzNFPdMWFOTyCjZHTpeIlwdiCjbnSgcYVie3W{ZXSgZYZ1\XJiMjDodpMh[nlibHnxeYllKHOlaX70bYxt[XSrb36gZ492dnSrbnegcYV1cG:mLDDJR|UxKD1iMT64N{DPxE1w Mk\1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl7NUS2PFIoRjJ7OUW0OlgzRC:jPh?=

... Click to View More Cell Line Experimental Data

In vivo Dapagliflozin reduces blood glucose levels by 55% after 0.1 mg/kg oral dose in hyperglycemic streptozotocin (STZ) rats, which is in part to the metabolic stability conferred by the C-glucoside linkage. Dapagliflozin displays a favorable absorption, distribution, metabolism, and excretion (ADME) profile and is orally bioavailable. [1] Dapagliflozin (1 mg/kg) causes significant dose-dependent glucosuria and increase in urine volume in normal rats over 24 hours post-dose. Dapagliflozin induces increase in urine glucose and urine volume excretion at 6 hours post-dose in Zucker diabetic fatty (ZDF) rats. Dapagliflozin lowers fasting and fed glucose levels in ZDF rats even by 2 weeks of treatment, without any marker of renal or liver toxicity. [2] Dapagliflozin significantly reduces the development of hyperglycaemia, with lowered blood glucose. Dapagliflozin could improve the insulin sensitivity, reduce β-cell mass and the development of impaired pancreatic function. [4]

Protocol

Animal Research:[1]
- Collapse
  • Animal Models: Normal Sprague Dawley rats or streptozotocin induced male Sprague Dawley rats
  • Dosages: 0.01-10 mg/kg (1 mL/kg) followed by a 50% glucose solution (2 g/kg)
  • Administration: Dosed orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 82 mg/mL (200.55 mM)
Ethanol 17 mg/mL (41.57 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40%PEG300+5% tween80+50% H2O
For best results, use promptly after mixing.
4.1 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 408.87
Formula

C21H25ClO6

CAS No. 461432-26-8
Storage powder
in solvent
Synonyms BMS-512148
Smiles CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04570865 Not yet recruiting Drug: Dapagliflozin|Device: CardioMEMS Heart Failure Systolic Scripps Health December 1 2020 Phase 4
NCT04534270 Recruiting Drug: Dapagliflozin Proteinuria Children''s Hospital of Fudan University July 6 2020 Phase 4
NCT04445714 Not yet recruiting Drug: dapagliflozin and saxagliptin Type 2 Diabetes Mellitus AstraZeneca June 30 2020 Phase 4
NCT04035031 Recruiting Drug: Forxiga 10mg|Drug: Placebo Diabetes Mellitus Type 1 University Hospital Inselspital Berne January 9 2020 Phase 3
NCT04120623 Not yet recruiting Drug: Dapagliflozin 10 MG|Drug: Insulin Aspart Type 2 Diabetes Mellitus Nanjing First Hospital Nanjing Medical University October 1 2019 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

SGLT Signaling Pathway Map

Related SGLT Products

Tags: buy Dapagliflozin | Dapagliflozin supplier | purchase Dapagliflozin | Dapagliflozin cost | Dapagliflozin manufacturer | order Dapagliflozin | Dapagliflozin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID